
Issuer Direct Corp. Electronic EDGAR Proof

Job Number:	156233
Filer:	SUNSHINE BIOPHARMA INC.
Form Type:	10-Q
Reporting Period / Event Date:	09/30/15
Customer Service Representative:	SD
Revision Number:	.

This proof may not fit on letter-sized (8.5 x 11 inch) paper. If copy is cut off, please print to a larger format, e.g., legal-sized (8.5 x 14 inch) paper or oversized (11 x 17 inch) paper.

Accuracy of proof is guaranteed ONLY if printed to a PostScript printer using the correct PostScript driver for that printer make and model.

(this header is not part of the document)

EDGAR Submission Header Summary

Submission Type	10-Q
Live File	on
Return Copy	on
Exchange	NONE
Confirming Copy	off
Filer CIK	0001402328
Filer CCC	xxxxxxxx
Period of Report	09/30/15
Smaller Reporting Company	on
Notify via Filing website Only	off

Documents

10-Q	sbfm_10q.htm Quarterly Report
EX-31.1	sbfm_ex311.htm Certification
EX-31.2	sbfm_ex312.htm Certification
EX-32	sbfm_ex32.htm Certification
GRAPHIC	figure1.jpg
GRAPHIC	figure2.jpg
GRAPHIC	table1.jpg

Module and Segment References

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Under
the Securities Exchange Act of 1934

For Quarter Ended: **September 30, 2015**

Commission File Number: **000-52898**

SUNSHINE BIOPHARMA INC.

(Exact name of small business issuer as specified in its charter)

Colorado

(State of other jurisdiction of incorporation)

20-5566275

(IRS Employer ID No.)

**469 Jean-Talon West
3rd Floor**

Montreal, Quebec, Canada H3N 1R4

(Address of principal executive offices)

(514) 764-9698

(Issuer's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of the registrant's only class of Common Stock issued and outstanding as of November 4, 2015, was 137,549,992 shares.

TABLE OF CONTENTS
PART I.
FINANCIAL INFORMATION

	<u>Page No.</u>
Item 1. Financial Statements	3
Unaudited Consolidated Balance Sheet as of September 30, 2015	3
Unaudited Statement of Operations for the Three and Nine Month Periods Ended September 30, 2015	4
Unaudited Consolidated Statement of Cash Flows for the for the Three and Nine Month Periods Ended September 30, 2015	5
Notes to Unaudited Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation.	13
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	22
Item 4. Controls and Procedures.	22

PART II
OTHER INFORMATION

Item		
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	23
	Signatures	24

Sunshine Biopharma, Inc.
Consolidated Balance Sheet

	Unaudited September 30, 2015	Audited December 31, 2014
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 125,225	\$ 143,423
Prepaid expenses	11,411	-
Total Current Assets	136,636	143,423
TOTAL ASSETS	\$ 136,636	\$ 143,423
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Current portion of note payable	418,640	480,124
Accounts payable	34,638	34,766
Interest payable	16,288	16,113
Total current liabilities	469,566	531,003
TOTAL LIABILITIES	469,566	531,003
COMMITMENTS AND CONTINGENCIES		
SHAREHOLDERS' EQUITY (DEFICIT)		
Preferred stock, Series A \$0.10 par value per share; Authorized 5,000,000 Shares; Issued and outstanding -0- shares.	-	-
Preferred stock, Series B \$0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 shares.	50,000	
Common Stock, \$0.001 per share; Authorized 200,000,000 Shares; Issued and outstanding 134,392,097 and 73,551,041 at September 30, 2015 and December 31, 2014 respectively	134,392	73,551
Capital paid in excess of par value	7,915,143	6,967,228
Accumulated comprehensive income	1,123	-
Accumulated (Deficit)	(8,433,588)	(7,428,359)
TOTAL SHAREHOLDERS' EQUITY (DEFICIT)	(332,930)	(387,580)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	\$ 136,636	\$ 143,423

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.
 Unaudited Consolidated Statement Of Operations and Comprehensive Loss

	Unaudited 3 Months Ended September 30, 2015	Unaudited 3 Months Ended September 30, 2014	Unaudited 9 Months Ended September 30, 2015	Unaudited 9 Months Ended September 30, 2014
Revenue:	\$ -	\$ -	\$ 1,708	\$ -
General & Administrative Expenses				
Accounting	2,700	1,620	60,260	38,820
Consulting	6,011	215,500	107,432	541,500
Legal	26,104	20,152	103,346	234,929
Licenses	64,986	30,000	259,094	183,333
Office	3,187	8,934	8,911	21,824
Officer remuneration	-	-	50,000	-
Public Relations	-	-	-	100,000
Research and Development	8,657	-	8,657	323,000
Stock Transfer Fee	1,408	1,221	10,043	5,408
Total G & A	113,053	277,427	607,743	1,448,814
(Loss) from operations	\$ (113,053)	\$ (277,427)	(606,035)	(1,448,814)
Other Income (expense):				
Foreign exchange gain	204	-	204	-
Interest expense	(9,755)	(3,422)	(49,186)	(151,679)
Gain from ineterst forgiveness	-	-	9,465	-
Loss on debt conversions	(80,211)	-	(359,677)	-
Total Other (Expense)	(89,762)	(3,422)	(399,194)	(151,679)
Net (loss)	\$ (202,815)	\$ (280,849)	\$ (1,005,229)	\$ (1,600,493)
Basic (Loss) per common share	(0.00)	(0.00)	\$ (0.01)	\$ (0.02)
Weighted Average Common Shares Outstanding	130,069,136	67,820,603	109,827,383	64,688,934
Net Income (Loss)	\$ (202,815)	\$ (280,849)	\$ (1,005,229)	\$ (1,600,493)
Other comprehensive income:				
Gain from foreign exchange transactions	(3,234)	-	1,123	-
Comprehensive (Loss)	(206,049)	(280,849)	(1,004,106)	(1,600,493)
Basic (Loss) per common share	(0.00)	(0.00)	\$ (0.01)	\$ (0.02)
Weighted Average Common Shares Outstanding	130,069,136	67,820,603	109,827,383	64,688,934

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.
 Unaudited Consolidated Statement Of Cash Flows

	Unaudited 9 Months Ended September 30, 2015	Unaudited 9 Months Ended September 30, 2014
Cash Flows From Operating Activities:		
Comprehensive (Loss)	\$ (1,004,106)	\$ (1,600,493)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock issued for licenses, services, and other assets	116,500	1,085,985
Stock issued for payment interest	6,406	75,000
Loss on debt conversion	359,677	-
Stock issued for payment of expenses	9,160	120,854
(Increase) in prepaid expenses	(11,411)	(6,419)
Increase (decrease) in Accounts Payable	(129)	27,511
Increase in interest payable	175	6,679
Net Cash Flows (used) in operations	<u>(523,728)</u>	<u>(290,883)</u>
Cash Flows From Investing Activities:		
Net Cash Flows (used) in Investing activities	<u>-</u>	<u>-</u>
Cash Flows From Financing Activities:		
Proceed from note payable	232,840	273,500
Note payable used to pay origination fees & interest	36,140	50,000
Sale of common stock	<u>236,550</u>	<u>110,000</u>
Net Cash Flows provided by financing activities	<u>505,530</u>	<u>433,500</u>
Net Increase (Decrease) In Cash and cash equivalents	(18,198)	142,617
Cash and cash equivalents at beginning of period	<u>143,423</u>	<u>31,240</u>
Cash and cash equivalents at end of period	<u>\$ 125,225</u>	<u>\$ 173,857</u>
Supplementary Disclosure Of Cash Flow Information:		
Stock issued for services, licenses and other assets	<u>\$ 116,500</u>	<u>\$ 818,585</u>
Stock issued for note conversions including interest	<u>\$ 705,707</u>	<u>\$ -</u>
Stock issued for interest	<u>\$ -</u>	<u>\$ 170,000</u>
Stock issued for payment of expenses	<u>\$ -</u>	<u>\$ 43,333</u>
Loan proceeds used to pay expenses	<u>\$ -</u>	<u>\$ 40,000</u>
Cash paid for interest	<u>\$ -</u>	<u>\$ -</u>
Cash paid for income taxes	<u>\$ -</u>	<u>\$ -</u>

See Accompanying Notes To These Financial Statements.

Note 1 - Descriptions of Business

The Company was incorporated on August 31, 2006 in the State of Colorado under the name Mountain West Business Solutions, Inc. Effective October 15, 2009, the Company engaged in a reverse merger and changed its name to "Sunshine Biopharma, Inc." The financial statements represent the consolidated activity of the merged entity. As a result of the reverse merger, the Company's principal business became conducting research, development and commercialization of drugs for the treatment of various forms of cancer, specifically the Company's proprietary cancer fighting drug, Adva-27a.

In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. ("Sunshine Canada") for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Canada is currently working on securing a Drug Establishment License from Health Canada and signing manufacturing, marketing, sales and distribution contracts for various generic pharmaceuticals for sale in Canada and overseas. All references in this report to the "Company" refer to Sunshine Biopharma, Inc. and its subsidiary companies.

During the last three month period the Company has continued to raise money through stock sales and borrowings, including the issuance of convertible promissory notes.

The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's current technology before another company develops a similar technology and drug.

Note 2 - Summary of Significant Accounting Policies

This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements. This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Note 2 - Summary of Significant Accounting Policies (continued)

USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statements of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of \$125,225 and \$143,423 as of September 30, 2015 and December 31, 2014, respectively. At times such cash balances may be in excess of the FDIC limit of \$250,000.

EARNINGS PER SHARE

The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

There were no potentially dilutive instruments outstanding during the interim period ended September 30, 2015, or the year ended December 31, 2014.

INCOME TAXES

The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.

Note 2 - Summary of Significant Accounting Policies (continued)

FOREIGN CURRENCY

The Company has operations in Canada, however the functional and reporting currency is in U.S. dollars.

Due to the functional and reporting currency both being in U.S. dollars, ASC 830-10-45-17 states that a currency translation is not necessary.

REVENUE RECOGNITION

On occasion, the Company performs consulting services. It recognizes revenue at the time the service is rendered.

GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The Company's continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, to attain profitable operations. The Company will need to secure additional funds through various means, including an acquisition, equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional debt or equity financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company's stockholders, restrictive covenants or high interest costs. The Company's long-term liquidity also depends upon its ability to generate revenues and achieve profitability.

The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 3 – Unaudited Financial Information

The unaudited financial information included for the three and nine month interim periods ended September 30, 2015, was taken from the books and records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations

Note 3 – Unaudited Financial Information (continued)

for the three month interim period ended September 30, 2015 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2015. See the Notes in our Form 10-K for our fiscal year ended December 31, 2014 to the consolidated financial statements included therein for a complete summary of our significant accounting policies.

Note 4 – Notes Payable

At September 30, 2015, the Company had outstanding loans of \$12,500 accruing interest at a rate of 12%, \$161,140 accruing interest at 12%, and 245,000 accruing interest at 8%. At September 30, 2015 and December 31, 2014 accrued interest was \$16,288 and \$16,113, respectively.

Note 5 – Issuance of Common Stock

During the nine months ended September 30, 2015, the Company issued, 60,841,056 shares of its \$0.001 par value Common Stock. Of these, 39,041,056 shares valued at \$705,707 were issued on conversion of convertible promissory notes, reducing debt by \$342,804 and generating a loss of \$350,212 for the period.

In March 2015, the Company undertook a private offering of Common Stock in Canada pursuant to Regulation S promulgated under the Securities Act of 1933, as amended and accepted two subscriptions of 10,000,000 shares each for \$150,000 Canadian, aggregating \$300,000 Canadian or approximately \$236,550 US. This offering was terminated in September 2015.

The Company declared no dividends through September 30, 2015.

Note 6 – Issuance of Series "B" Preferred Stock

During the nine month period ended September 30, 2015, the Company authorized 500,000 shares of \$0.10 par value Series "B" Preferred stock. The stock gives the holder the right to 1,000 votes per share. 500,000 shares of Series "B" Preferred Shares were issued to the CEO of the Company in exchange for services valued at \$50,000.

Note 7 – Convertible Notes

A Note with a Face Value \$128,000, bearing interest at 10% was issued on November 27, 2014 and was due May 27, 2015. The Note was issued at a premium and is convertible from the date of issuance into \$0.001 par value Common Stock at a price of \$0.20 per share. On June 30, 2015, holder of the Note and the Company renewed this note with the addition of accrued interest amounting to \$7,540 and an origination fee of \$25,600. The new Note has a Face Value of \$161,140, an origination fee of \$32,228 and accrues interest

Note 7 – Convertible Notes (continued)

at 12%. The new Note is convertible anytime from the date of issuance into \$0.001 par value Common Stock at a 35% discount from market price. Any gain or loss will be recognized at conversion.

A Note having a remaining balance of \$94,624 as of December 31, 2014 was fully converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. In connection therewith, 11,513,839 shares of \$0.001 Common Stock valued at \$242,415 were issued reducing the debt by \$94,624 and generating a loss on conversion of \$147,791 and interest write off of \$6,648 for a total net loss of \$141,143.

A convertible Note with an original Face Value of \$113,500 was fully converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. 12,395,296 shares of \$0.001 par value Common Stock valued at \$203,144 were issued in connection therewith generating a loss of \$89,644 on conversion.

A Note having a Face Value of \$53,500 with interest at 8% was due August 17, 2015. The Note was fully converted as of June 30, 2015. \$53,500 in principal and \$2,140 in interest was converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. In connection therewith, 4,622,793 shares of \$0.001 par value Common Stock valued at \$88,777 were issued generating a loss of \$33,137 on conversion.

A Note having a Face Value of \$78,000 with interest at 8% is due November 14, 2015. \$55,000 of principal and \$4,266 in interest and was fully converted into \$0.001 par value Common Stock during the nine month period ended September 30, 2015. 10,509,128 shares of \$0.001 par value Common Stock valued at \$128,972 generating a loss of \$89,105 were issued on conversion. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

In April 2015, the Company received monies in exchange for a note having a Face Value of \$83,500 with interest at 8%, which is due January 23, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

In May 2015, the Company received monies in exchange for a note having a Face Value of \$78,500 with interest at 8%, which is due March 1, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

Note 7 – Convertible Notes (continued)

In August 2015, the Company received monies in exchange for a note having a Face Value of \$83,000 with interest at 8%, which is due March 1, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

Note 8 – Earnings (Loss) Per Share

Earnings (loss) per share is computed using the weighted average number of common shares outstanding during the period. The Company has adopted ASC 260 (formerly SFAS128), "Earnings Per Share".

Note 9– Financial Statements

For a complete set of footnotes, reference is made to the Company's Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission and the audited financial statements included therein.

Note 10 - Income Taxes

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

Deferred income tax arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

At the year ended December 31, 2015, and the nine month period ended September 30, 2015, the Company had approximately \$8,433,588 and \$7,428,359, respectively in unused federal net operating loss carryforwards, which begin to expire principally in the year 2026. A deferred tax asset at each date of approximately \$3,257,895 and \$2,869,575 respectively resulting from the loss carry forwards has been offset by a 100% valuation allowance. The change in the valuation allowance for the periods ended September 30, 2015 and December 31, 2014 was approximately \$388,320 and \$747,185 respectively.

Note 11 – Subsequent Events

Effective October 8, 2015, the Company executed a Patent Purchase Agreement (the "Purchase Agreement"), with Advanomics Corporation, Montreal, Canada ("Advanomics"), pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 (the "Patent") for our anticancer compound, Adva-27a. The Purchase Agreement provides us with direct ownership of the Patent, which

Note 11 – Subsequent Events (continued)

includes all rights to this intellectual property within the United States. Prior, we had been licensing the right to use the Patent from Advanomics pursuant to the terms of a License Agreement, as amended (the "License Agreement"). Our obligations under the License Agreement required us to pay Advanomics a perpetual annual license fee of \$360,000 and reimburse Advanomics for all research and development expenses incurred by Advanomics in connection with Adva-27a, the Licensed Material (as defined in the License Agreement). The Purchase Agreement terminates the License Agreement and all obligations thereunder and provides for purchase of the Patent for twelve (12) consecutive annual payments of \$360,000 starting in 2016. Advanomics will retain a security interest in the Patent until all payments due under the Purchase Agreement have been made. Dr. Steve Slilaty, our CEO and principal shareholder, is also the principal officer and shareholder of Advanomics.

On October 28, 2015, the holder of a convertible note having a principal balance of \$83,500 as of September 30, 2015, elected to convert \$12,000 in principal amount into 3,157,895 shares of \$0.001 par value Common Stock, leaving a principal balance of \$71,500.

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by any forward-looking statements.

Factors that may cause or contribute actual results to differ from these forward-looking statements include, but are not limited to, for example:

- adverse economic conditions;
- the inability to attract and retain qualified senior management and technical personnel; and
- other risks and uncertainties related to our changing market and our business strategy.

All forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements or other information contained herein. Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. We disclose important factors that could cause our actual results to differ materially from expectations under “Risk Factors” and elsewhere in this current report. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the Quarterly Report on Form 10-Q. All subsequent written and oral forward-looking statements concerning other matters addressed in this Quarterly Report on Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Quarterly Report on Form 10-Q.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

PART I

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results

or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

OVERVIEW AND HISTORY

We were incorporated in the State of Colorado on August 31, 2006 under the name "Mountain West Business Solutions, Inc." During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies. Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock. As a result of this transaction our then officers and directors resigned their positions with us and were replaced by our current management. As a result of this transaction we also changed our name to "Sunshine Biopharma, Inc." On December 21, 2011, Advanomics Corporation exercised its right to convert the 850,000 shares of Series "A" Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Our principal place of business is located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada H3N 1R4. Our phone number is (514) 764-9698 and our website address is www.sunshinebiopharma.com.

We have not been subject to any bankruptcy, receivership or similar proceeding.

RESULTS OF OPERATIONS

Comparison of Results of Operations for the Nine Months Ended September 30, 2015 and 2014

For the nine months ended September 30, 2015 and 2014 we did not generate any material revenues. We did generate gross revenues of \$1,708 during the nine months ended September 30, 2015 from scientific consulting services provided to a local company in Montreal (Canada). We did not generate any revenues in 2014.

General and administrative expenses during the nine month period ended September 30, 2015 were \$607,743, compared to general and administrative expense of \$1,448,814 incurred during the nine month period ended September 30, 2014, a decrease of \$841,071. This decrease is primarily attributable to (i) a decrease of \$314,343 in research and development ("R&D") expenses. We incurred nominal R&D charges during the nine months ended September 30, 2015, as our management concentrated on raising money to manufacture our drug; (ii) a decrease of \$434,068 in consulting fees. The decrease in consulting fees was as a result of our not using consultants in our fund raising efforts; and (iii) a decrease of \$110,143 in professional fees. In addition, we had incurred \$100,000 in public relations fees during the nine months ended September 30, 2014 that we did not incur during the similar period in 2015. We incurred \$50,000 in executive compensation during the nine months ended September 30, 2015, that we did not incur in the similar period in 2014. License fees payable to Advanomics Corporation also increased by \$75,761, more as a function of when payments were tendered. Our annual license fee did not increase from 2014 to 2015. Subsequently, we terminated this license and have acquired the related patent rights. See "Plan of Operation - Subsequent Events," below.

We also incurred \$49,186 in interest expense and \$350,212 in losses from debt conversion and interest write-offs during the nine months ended September 30, 2015, compared to \$151,679 in interest expense and no losses from debt conversion during the similar period in 2014 due to the fact that we had no convertible debt during that period.

As a result, we incurred a net loss of \$1,005,229 (approximately \$0.01 per share) for the nine month period ended September 30, 2015, compared to a net loss of \$1,600,493 (approximately \$0.02 per share) during the nine month period ended September 30, 2014.

Comparison of Results of Operations for the Three Months Ended September 30, 2015 and 2014

For the three months ended September 30, 2015 and 2014 we did not generate any revenues.

General and administrative expenses during the three month period ended September 30, 2015 were \$113,053, compared to general and administrative expense of \$277,427 incurred during the three month period ended September 30, 2014, a decrease of \$114,374. This decrease is attributable to a decrease of \$209,489 in consulting fees paid in 2014. However, licensing fee payments increased by approximately \$34,000 during the three months ended September 30, 2015.

We also incurred \$9,755 in interest expense and \$70,746 in losses from debt conversion during the three months ended September 30, 2015, compared to \$3,422 in interest expense and no losses from debt conversion during the similar period in 2014 due to the fact that we had no convertible debt during that period.

As a result, we incurred a net loss of \$193,350 (less than \$0.01 per share) for the three month period ended September 30, 2015, compared to a net loss of \$280,849 (less than \$0.01 per share) during the three month period ended September 30, 2014.

Because we did not generate any material revenues since our inception, following is our Plan of Operation.

PLAN OF OPERATION

We are currently a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The preclinical studies for our lead compound, Adva-27a, a multi-purpose antitumor compound, were successfully completed in late 2011. We are now continuing our clinical development of Adva-27a by conducting the next sequence of steps comprised of Good Manufacturing Practice ("GMP") manufacturing of a 2 kilogram quantity, Investigational New Drug ("IND")-enabling studies, regulatory filing and Phase I clinical trials. We plan to conduct our Phase I clinical trials for Adva-27a at the Jewish General Hospital, Montreal, Canada, one of McGill University's Hospital Centers. The planned indication will be pancreatic cancer in parallel to multidrug resistant breast cancer as Adva-27a has shown a positive effect on both of these cancer types for which there is currently little or no treatment options available. See "Clinical Trials" below.

We have been licensing our Adva-27a technology on an exclusive basis from Advanomics Corporation and on October 8, 2015 we acquired the patent covering that technology (See "Subsequent Events" below). In addition, we are planning to initiate our own research and development program as soon as practicable once financing is in place. There are no assurances that we will obtain the financing necessary to allow us to implement this aspect of our business plan, or to enter clinical trials. See "Liquidity and Capital Resources," below.

Our Lead Compound (Adva-27a)

Our initial drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. If we are successful in our current financing efforts, Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast cancer in late 2016 (see "Clinical Development Path" and "Clinical Trials" below). Etoposide, which is also a derivative of Podophyllotoxin, is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Like Etoposide, Adva-27a is a Topoisomerase II inhibitor; however, unlike Etoposide and other anti-tumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells. Adva-27a is a new chemical entity and has been shown to have distinct and more desirable biological properties compared to Etoposide. Most notably, Adva-27a is very effective against multidrug resistant breast cancer cells while Etoposide has no activity against this aggressive form of cancer (see Figure 1). In other side-by-side studies against Etoposide as a reference, Adva-27a showed markedly improved cell killing activity in various other cancer types, particularly prostate, colon and lung cancer (see Table 1). Our preclinical studies to date have shown that:

- Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
 - Breast Cancer Cells (MCF-7/MDR)

- Small Cell Lung Cancer Cells (H69AR)
- Uterine Cancer (MES-SA/Dx5)
- Pancreatic Cancer (Panc-1)
- Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
- Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
- Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
- Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).
- Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
- Adva-27a does not inhibit tubulin assembly.

These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The manuscript entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” appeared in print in the October 2012 issue of the journal [ANTICANCER RESEARCH 32: 4423-4432 (2012)]. A copy of the full manuscript as it appeared in the journal is available on our website at www.sunshinebiopharma.com.




Figure 1

PERCENT INHIBITION OF CELL GROWTH AT 10 MICROMOLAR*								
Cell Line Cancer Type	KB Nasopharynx	PC3 Prostate	MCF7 Breast	MCF7/MDR MDR Breast**	SF268 Brain	HL60 Leukemia	HT29 Colon	A594 Lung
Etoposide	84	47	57	22	82	75	79	65
Adva-27a***	91	63	53	70	65	79	87	78

*Data published in PCT/FR2007/000697 **Multidrug resistant breast cancer ***Our lead compound

Table 1

Clinical Development Path

The early stage preclinical studies for our lead compound, Adva-27a, were successfully completed in late 2011 and the results have been published [ANTICANCER RESEARCH 32: 4423-4432 (2012)]. We have been delayed in our implementation of our clinical development program due to lack of funding, but, while there are no assurances, we now believe we may have secured this funding. If we do receive this funding, we will continue our clinical development program of Adva-27a by conducting the next sequence of steps comprised of the following:

- GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials
- IND-Enabling Studies
- Regulatory Filing (Fast-Track Status Anticipated)
- Phase I Clinical Trials (Multidrug Resistant Breast Cancer Indication)

GMP Manufacturing

On November 14, 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred to as “Lonza”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug (the “Lonza Agreement”). Lonza is one of the world’s leading and most-trusted manufacturers of pharmaceutical ingredients. Headquartered in Basel, Switzerland, Lonza has more than 40 major manufacturing facilities worldwide and is currently manufacturing 2 kilograms of our Adva-27a for clinical trials. The Lonza Agreement was effective November 10, 2014, has a term of 5 years, and may be extended or terminated earlier as provided in the Lonza Agreement.

In June 2015 we received a sample of the scale-up manufacturing process for evaluation and confirmation of adherence to specifications. Based upon our laboratory analyses, the sample meets all of the required chemical, physical and biological specifications. This paves the way for moving forward with large scale manufacturing of a 2-kilogram quantity for the IND-Enabling studies and clinical trials. If the timetable for generating the 2-kilogram quantity is met, of which there can be no assurance, and subject to receipt of the necessary financing, also for which no assurances can be provided, we expect to move into Phase I of our clinical trials in late 2016 or early 2017.

Pursuant to the terms of the Lonza Agreement, Lonza will manufacture our drug in accordance with current Good Manufacturing Practices (“cGMP”) in compliance with the regulations applicable in the U.S., Canada, Europe and other countries around the world relating to the manufacturing of medicinal products for human use. Lonza will build a master drug file for our Adva-27a drug and will have it ready for filing with regulatory authorities as may be required to secure ultimate drug approval. The Lonza Agreement provides for us to maintain one representative of our Company at their facility during the manufacturing process. Quality assurance and control is the responsibility of both Lonza and us during the process.

We have the right to inspect, test and approve all batches to insure compliance with the manufacturing specifications, which is required to be completed within 30 days after release of a batch. In the event of a dispute regarding compliance with the manufacturing specifications, the dispute will be resolved ultimately by independent analysis and testing. The Lonza Agreement contains customary warranties and disclaimers, confidentiality provisions as well as mutual indemnifications common in agreements of this type.

Clinical Trials

Adva-27a’s initial indication will be pancreatic cancer and multidrug resistant breast cancer for which there are currently little or no treatment options available. In June 2011 we concluded an agreement with McGill University’s Jewish General Hospital in Montreal, Canada to conduct Phase I clinical trials for these two indications. All aspects of the planned clinical trials in Canada will employ U.S. Food and Drug Administration (“FDA”) standards at all levels. If adequate funding is obtained, of which there is no assurance, we now anticipate that Phase I clinical trials will commence in late 2016 or early 2017 and we estimate that it will take 18 months to complete, at which time we expect to receive limited marketing approval for “compassionate-use” under the FDA and similar guidelines in Canada. *See* “Marketing,” below.


Marketing

According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. Given the terminal and limited treatment options available for the pancreatic cancer and multidrug resistant breast cancer indications we are planning to study, we anticipate being granted limited marketing approval (“compassionate-use”) for our Adva-27a following receipt of funding and a successful Phase I clinical trial. There are no assurances that either will occur. Such limited approval will allow us to make the drug available to various hospitals and health care centers for experimental therapy and/or “compassionate-use”, thereby generating some revenues in the near-term.

We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to manufacture and market our new drug.

Intellectual Property

Until October 8, 2015, we were the exclusive licensee for the U.S. territory of Advanomics Corporation's Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697). These patent applications, which are now issued in Europe, Canada, the United States (US 8,236,935) and elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation. Effective October 8, 2015, we executed a Patent Purchase Agreement (the "Purchase Agreement") with Advanomics Corporation, pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for our anticancer compound, Adva-27a. The Purchase Agreement provides us with direct ownership of the patent, which includes all rights to this intellectual property within the United States (See "Subsequent Events" below).



Our Lead Anti-Cancer Compound, Adva-27a, in 3D

Development of New Business

On July 25, 2014, we formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. While no assurances can be provided and subject to the availability of adequate financing, of which there is no assurance, we anticipate that Sunshine Biopharma Canada will soon secure a Drug Establishment License (DEL) from Health Canada and proceed to signing manufacturing, marketing, sales and distribution contracts for various generic pharmaceutical products. This new effort broadens our business scope and provides us with the opportunity to generate revenues in the near to mid-term. We anticipate revenues to be generated through the export of generic pharmaceuticals overseas. There are no assurances that we will be able to sign applicable contracts or generate profits from these anticipated new operations. In addition to revenue generation, we anticipate that as a result of these activities, Sunshine Biopharma Canada will then be well positioned for the marketing and distribution of Adva-27a, our flagship oncology drug candidate currently being developed for the treatment of pancreatic cancer and multidrug resistant breast cancer, provided that Adva-27a is approved for such marketing and distribution, of which there can be no assurance.

While no assurances can be provided, we are also planning to expand our product line through acquisitions and/or in-licensing as well as in-house research and development.

Subsequent Events

Effective October 8, 2015, we executed a Patent Purchase Agreement (the "Purchase Agreement"), with Advanomics Corporation, Montreal, Canada ("Advanomics"), pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 (the "Patent") for our anticancer compound, Adva-27a. The Purchase Agreement provides us with direct ownership of the Patent, which includes all rights to this intellectual property within the United States. Prior, we had been licensing the right to use the Patent from Advanomics pursuant to the terms of a License Agreement, as amended (the "License Agreement").

We believe the financial terms of the Purchase Agreement are more favorable to us than under the License Agreement. Our obligations under the License Agreement required us to pay Advanomics a perpetual annual license fee of \$360,000 and reimburse Advanomics for all research and development expenses incurred by Advanomics in connection with Adva-27a, the Licensed Material (as defined in the License Agreement). The Purchase Agreement terminates the License Agreement and all obligations thereunder and provides for purchase of the Patent for twelve

(12) consecutive annual payments of \$360,000 starting in 2016. Advanomics will retain a security interest in the Patent until all payments due under the Purchase Agreement have been made. Dr. Steve Sliaty, our CEO and principal shareholder, is also the principal officer and shareholder of Advanomics.

On October 28, 2015 the holder of a convertible note having a principal balance of \$83,500 as of September 30, 2015, elected to convert \$12,000 in principal amount into 3,157,895 shares of \$0.001 par value Common Stock, leaving a principal balance of \$71,500.

GOVERNMENT REGULATIONS

Our existing and proposed business operations are subject to extensive and frequently changing federal, state, provincial and local laws and regulations. We will be subject to significant regulations in the U.S. in order to obtain the approval of the FDA to offer our product on the market. The approximate procedure for obtaining FDA approval involves an initial filing of an IND application following which the FDA would give the go ahead with Phase I clinical (human) trials. If adequate funding is obtained, of which there is no assurance, we now anticipate that this process will commence in mid to late 2016 and we estimate that this procedure will take 18 months to complete. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly, following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion of Phase III, a request is made for marketing approval. Depending on various issues and considerations, the FDA could provide limited marketing approval on a humanitarian basis if the drug treats terminally ill patients with limited treatment options available. As of the date of this Report we have not made any filings with the FDA or other regulatory bodies in other jurisdictions. We have however had extensive discussions with clinicians at the McGill University's Jewish General Hospital in Montreal where we plan to undertake our Phase I study for pancreatic cancer and multidrug resistant breast cancer they believe that Health Canada is likely to grant us a so-called fast-track process on the basis of the terminal nature of the cancer types which we will be treating. There are no assurances this will occur.

EMPLOYEES

As of the date of this Report we have three (3) employees, our management. We anticipate that if we receive financing we will hire additional employees in the areas of accounting, regulatory affairs, marketing and laboratory personnel.

COMPETITION

We will be competing with publicly and privately held companies engaged in developing cancer therapies. There are numerous other entities engaged in this business that have greater resources, both financial and otherwise, than the resources presently available to us. Nearly all major pharmaceutical companies including Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name just a few, have on-going anti-cancer drug development programs and some of the drug they may develop could be in direct competition with our drug. Also, a number of small companies are also working in the area of cancer and could develop drugs that may be in competition with ours. However, none of these competitor companies can use molecules similar to ours as they would be infringing our patents.

TRADEMARKS-TRADENAMES

Until October 8, 2015, we were the exclusive licensee for the U.S. territory of Advanomics' Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697). These patent applications, which are now issued in Europe, Canada, the United States (8,236,935) and elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics.

On October 8, 2015 we executed a patent purchase agreement with Advanomics Corporation, pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for Adva-27a (See "Subsequent Events" above).

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2015, we had cash or cash equivalents of \$125,225.

Net cash used in operating activities was \$523,728 during the nine month period ended September 30, 2015, compared to \$290,883 for the nine month period ended September 30, 2014. We anticipate that overhead costs in current operations will increase in the future once our research and development activities discussed above increase.

Cash flows from financing activities were \$505,530 for the nine month periods ended September 30, 2015, compared to \$433,500 during the nine months ended September 30, 2014. Cash flows used by investing activities were \$0 for the nine month periods ended September 30, 2015 and 2014.

At September 30, 2015, we had outstanding loans of \$12,500 accruing interest at a rate of 12%, \$161,140 accruing interest at 12%, and 245,000 accruing interest at 8%. At September 30, 2015 and December 31, 2014 accrued interest was \$16,288 and \$16,113, respectively.

During the nine months ended September 30, 2015, we issued, 60,841,056 shares of our \$0.001 par value Common Stock. Of these, 39,041,056 shares valued at \$705,707 were issued on conversion of convertible promissory notes, reducing debt by \$342,804 and generating a loss of \$350,212 for the period.

In March 2015, we undertook a private offering of Common Stock in Canada pursuant to Regulation S promulgated under the Securities Act of 1933, as amended and accepted two subscriptions of 10,000,000 shares each for \$150,000 Canadian, aggregating \$300,000 Canadian or approximately \$236,550 US. This offering was terminated in September 2015. We utilized the proceeds derived from the sale of these shares for working capital.

A Note with a Face Value \$128,000, bearing interest at 10% was issued on November 27, 2014 and was due May 27, 2015. The Note was issued at a premium and is convertible from the date of issuance into \$0.001 par value Common Stock at a price of \$0.20 per share. On June 30, 2015, we and the holder of the Note renewed this note with the addition of accrued interest amounting to \$7,540 and an origination fee of \$25,600. The new Note has a Face Value of \$161,140, an origination fee of \$32,228 and accrues interest at 12%. The new Note is convertible anytime from the date of issuance into \$0.001 par value Common Stock at a 35% discount from market price. Any gain or loss will be recognized at conversion.

A Note having a remaining balance of \$94,624 as of December 31, 2014 was fully converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. In connection therewith, 11,513,839 shares of our Common Stock valued at \$242,415 were issued reducing the debt by \$94,624 and generating a loss on conversion of \$147,791 and interest write off of \$6,648 for a total net loss of \$141,143.

A convertible Note with an original Face Value of \$113,500 was fully converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. 12,395,296 shares of our Common Stock, valued at \$203,144, were issued in connection therewith generating a loss of \$89,644 on conversion.

A Note having a Face Value of \$53,500 with interest at 8% was due August 17, 2015. The Note was fully converted as of June 30, 2015. \$53,500 in principal and \$2,140 in interest was converted into \$0.001 par value Common Stock during the six month period ended June 30, 2015. In connection therewith, 4,622,793 shares of our Common Stock valued at \$88,777, were issued generating a loss of \$33,137 on conversion.

A Note having a Face Value of \$78,000 with interest at 8% is due November 14, 2015. \$55,000 of principal and \$4,266 in interest and was fully converted into \$0.001 par value Common Stock during the nine month period ended September 30, 2015. 10,509,128 shares of \$0.001 par value Common Stock valued at \$128,972 generating a loss of \$89,105 were issued on conversion. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

In April 2015, we received monies in exchange for a note having a Face Value of \$83,500 with interest at 8%, which is due January 23, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value

Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

In May 2015, we received monies in exchange for a note having a Face Value of \$78,500 with interest at 8%, which is due March 1, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

In August 2015, we received monies in exchange for a note having a Face Value of \$83,000 with interest at 8%, which is due March 1, 2016. The Note is convertible after 180 days from issuance into \$0.001 par value Common Stock at a price 35% below market value. We estimate that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

On April 23, 2014, we entered into an Investment Agreement (the "Investment Agreement") with Dutchess Opportunity Fund, II, LP ("Dutchess"), for the sale of up to \$2.5 million of shares of our Common stock over a three-year commitment period. Under the terms of the Investment Agreement, we may, from time to time and in our sole discretion, issue shares of our Common Stock to Dutchess at a price equal to ninety percent (90%) of the lowest daily volume weighted average price during a Trading Day of our Common Stock during the five (5) consecutive Trading Days immediately preceding the Put Notice Date, up to \$2.5 million. In connection with the Investment Agreement, we also issued to Dutchess an engagement fee in the form of 400,000 "restricted" shares of our Common Stock.

The amount of each tranche under the Investment Agreement is limited to maximum \$100,000 and we may only issue a Put Notice (as defined under the Investment Agreement) ten (10) Trading Days after each prior Put Notice Date. We are not obligated to utilize any of the \$2.5 million available under the Investment Agreement and there are no minimum commitments or minimum use penalties.

The Investment Agreement does not impose any restrictions on our operating activities. During the term of the Investment Agreement, Dutchess is prohibited from engaging in any short selling or hedging transactions, either directly or indirectly, related to our Common Stock.

On August 7, 2014, we elected to issue our initial put notice to Dutchess, wherein we requested that Dutchess purchase 930,233 shares of our Common Stock for \$100,000. We utilized the proceeds from the sale of these shares to repay debt.

During the nine month period ended September 30, 2015, we authorized 500,000 shares of \$0.10 par value "Series B" Preferred stock. The stock gives the holder the right to 1,000 votes per share. 500,000 shares of "Series B" preferred shares were issued to our CEO in exchange for services valued at \$50,000.

We are not generating revenue from our operations, and our ability to implement our business plan for the future will depend on the future availability of financing. Such financing will be required to enable us to further develop our drug research and development capabilities and continue operations. We intend to raise funds through private placements of our Common Stock and through short-term borrowing. We estimate that we will require approximately \$5 million in debt and/or equity capital to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital. While we have engaged in discussions with various investment banking firms and venture capitalists to provide us these funds, as of the date of this report we have not reached any agreement with any party that has agreed to provide us with the capital necessary to effectuate our business plan. Our inability to obtain sufficient funds from external sources when needed will have a material adverse effect on our plan of operation, results of operations and financial condition.

Our cost to continue operations as they are now conducted is nominal, but these are expected to increase once we commence Phase I clinical trials. We do not have sufficient funds to cover the anticipated increase in these expenses. We need to raise additional funds in order to continue our existing operations, to initiate research and development activities, and to finance our plans to expand our operations for the next year. If we are successful in raising additional funds, our research and development efforts will continue and expand.

INFLATION

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine month period ended September 30, 2015.

CRITICAL ACCOUNTING ESTIMATES

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures - Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of September 30, 2015, at the reasonable assurance level. We believe that our consolidated financial statements presented in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations - Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting - There were no changes in our internal control over financial reporting during the nine month period ended September 30, 2015, which were identified in conjunction with management's evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In February 2015 we filed an action in the Circuit Court of the 11th Judicial Circuit for Miami-Dade County, Florida against Justin Keener, d/b/a JMJ Financial, arising out of a convertible note that we issued to the defendant. The complaint alleges among other things, claims of usury, fraudulent inducement, breach of contract, and injunctive and declaratory relief. On October 14, 2015 a mediation meeting was held but no settlement agreement was reached. The case is now anticipated to proceed to trial.

We are a defendant to one outstanding matter of litigation but do not believe it presents any material potential liability. We are not party to any other material legal proceedings, nor have any such actions been threatened against us.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended September 30, 2015, we issued, 60,841,056 shares of our Common Stock. Of these, 39,041,056 shares valued at \$705,707 were issued on conversion of convertible promissory notes, reducing debt by \$342,804 and generating a loss of \$350,212 for the period.

In March 2015, we undertook a private offering of Common Stock in Canada pursuant to Regulation S promulgated under the Securities Act of 1933, as amended and accepted two subscriptions of 10,000,000 shares each for \$150,000 Canadian, aggregating \$300,000 Canadian or approximately \$236,550 US. This offering was terminated in September 2015. We used the proceeds from the sale of these shares for working capital.

During the nine month period ended September 30, 2015, we authorized 500,000 shares of our \$0.10 par value Series "B" Preferred Stock. The stock gives the holder the right to 1,000 votes per share. 500,000 shares of Series "B" Preferred Shares were issued to our CEO in consideration for services valued at \$50,000. We relied upon the exemption from registration provided by Section 4(2)(a) under the Securities Act of 1933, as amended, to issue these shares.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURE

Not Applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on November 4, 2015.

SUNSHINE BIOPHARMA, INC.

By: s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty,
Principal Executive Officer

By: s/ Camille Sebaaly
Camille Sebaaly,
Principal Financial Officer and
Principal Accounting Officer

**CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Steve N. Slilaty, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
-

- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 4, 2015

s/ Steve N. Slilaty
Steve N. Slilaty, Chief Executive Officer

**CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Camille Sebaaly, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
-

- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 4, 2015

s/ Camille Sebaaly
Camille Sebaaly, Chief Financial Officer

**CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this quarterly report of Sunshine Biopharma, Inc. (the "Company") on Form 10-Q for the nine month period ended September 30, 2015, as filed with the Securities and Exchange Commission on November 4, 2015 (the "Report"), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 4, 2015

s/ Steve N. Slilaty
Steve N. Slilaty, Chief Executive Officer

Dated: November 4, 2015

s/ Camille Sebaaly
Camille Sebaaly, Chief Financial Officer